Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study G · 2024
Read Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis by James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study G (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10842202.txt.
Description
James Howard and co-authors report in a study whose head gives 2023 as its year interim results from a long extension trial of a myasthenia drug. The illness weakens muscles through antibody attack at the nerve junction. The drug efgartigimod clears those antibodies by blocking their recycling route.
The open label extension ran up to three years across many centers worldwide. Dosing came in cycles of four weekly infusions, retimed by clinical judgment per patient. Of 151 who rolled over, 145 got at least one dose in the extension. Most, 84.8%, reported at least one side effect during the long run. Daily living and strength scores tracked benefit across the cycles given.
Catalog record
| CREATOR | James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study G |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |